NDAORAL SUSPENSIONTABLETPriority Review
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
Priority Review
DOLUTEGRAVIR SODIUM (dolutegravir sodium) by Viatris is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()].
Drug data last refreshed 8h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Dolutegravir sodium is a fixed-dose combination antiretroviral tablet combining abacavir, dolutegravir, and lamivudine for the treatment of HIV-1 infection. It works by inhibiting HIV integrase and reverse transcriptase enzymes, preventing viral replication. This oral suspension/tablet formulation simplifies treatment regimens for HIV-positive patients.
Pre-Launch
Pre-launch stage indicates team expansion opportunity for regulatory, commercial operations, and early sales infrastructure roles.
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Pre-launch stage offers opportunity to build foundational commercial and medical infrastructure for an established mechanism in a specialized indication. Career growth depends on successful market entry execution and competitive positioning against entrenched HIV specialists.
Brand ManagerField Sales Representative
Worked on DOLUTEGRAVIR SODIUM at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.